Pepcid AC garners leading share of antacid market since June launch -- J&J/Merck.

PEPCID AC SHARE OF HEARTBURN CATEGORY PEGGED AT OVER 20% by Johnson & Johnson/Merck. The company said in a Sept. 5 legal document that Pepcid AC has captured more than 20% of the $800 mil. "heartburn relief" category in "recent weeks." J&J/Merck launched the Rx-to-OTC switch H2 antagonist in June ("The Tan Sheet" June 12, p. 3).